ViiV Healthcare Company;Janssen Sciences Ireland Unlimited Company
发明人:
CAMPBELL, Kenneth Churchill,DELAET, Urbain Alfons C.,GOODRICH, James M.,GUAQUIÈRE, Juliette Segolène,LAUGHERY, Thomas,LIMET, Dominique J.,POTTAGE, John C.,RENOU, Ludovic Sylvain Marc,SCOTT, Trevor R.
申请号：
AU2018291076
公开号：
AU2018291076A1
申请日:
2018.06.27
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.
